Test Medical

The Ultimate Blood Cancer Screen contains the following tests male only):

Complete Blood Count (CBC) w/ Differential Carcinoembryonic Antigen (CEA) Test

C-Reactive Protein (CRP) Test Kidney Function Profile

Liver Function Profile Sedimentation Rate, Westergen (ESR)

Iron, Serum Complete Urinalysis Profile

Comprehensive Metabolic Panel

Carbohydrate Antigen (CA) 19-9

Prostate Cancer Profile** Lipid-Associated Sialic Acid (LASA)

What is cancer screening?

Cancer screening refers to tests that can be done to look for signs of cancer or to see if you are likely to develop cancer. Screening

tests that look for cancer are called early detection tests. Screening tests that show cancer is likely to develop are called preventive

screening.

An example of an early detection test is a mammogram, which can show cancerous breast tumors when they are still tiny. An

example of a test that can be used for preventive screening is a Pap test. The Pap test can show cell changes likely to turn into

cancer before the actual cancer has developed.

Why is cancer screening important?

Cancer screening saves lives and improves the quality of life for cancer survivors.

There have been many advances in cancer treatment over the past few years. Cancer no longer has to be a death sentence. Early

treatment often results in a cure. Many people are now living well after a cancer diagnosis, often because their cancer was

diagnosed and treated very early. For example, precancerous changes found with a Pap test can easily be treated and cured before

cancer develops. A small breast cancer may be seen on a mammogram up to 2 years before it can be felt with a breast exam. The

cancer can then be treated early, greatly increasing the chances for survival

Blood Test for Cancer?

If Protein Is Present, Cancer Is Present, Say Researchers

By Charlene Laino

WebMD Health News

Sept. 13, 2006 (Chicago) -- Researchers have identified a protein in the blood present only in people with cancer that may help

doctors spot cancer early.

The protein, called tNOX, is the first tumor marker for all cancers ever described, says D. James Morre, PhD, distinguished

professor of medicinal chemistry at Purdue University in West Lafayette, Ind.

"If tNOX is present, cancer is present," he tells WebMD. "Presumably, the more there is, the worse the disease."

Putting tNOX to the Test

Normal cells have the NOX enzyme only when they are dividing in response to growth hormone signals. In contrast, cancer cells

have NOX activity at all times.

This overactive form of NOX, known as tNOX -- for tumor-associated NOX -- has long been thought to be vital for the growth of

cancer cells because drugs that inhibit tNOX activity also block tumor cell growth.

In two new studies presented here at a meeting of the American Association for Cancer Research, Morre and colleagues put the

protein to the test.

It passed with flying colors, he says.

Test Predicts Prostate Cancer Progression

The first study involved 19 men with advanced metastatic prostate cancer.

The researchers found that the nine men whose prostate cancer continued to progress -- based on their PSA levels, a blood test

elevated in most men with prostate cancer -- had 60% more tNOX in their blood compared with the 10 men with stable or falling

PSA levels.

"It's the first demonstration that we have, assuming that PSA levels indicate major tumor burden in some fashion, that there is a

really good correlation between tNOX levels and response to therapy," Morre says.

He believes the test will be even more useful than PSA. The reason: A man can have high PSA levels and not have cancer. The

tNOX enzyme, on the other hand, is only present if there is cancer.

Test Spots Lung Cancer

The second study looked at tNOX levels in 421 volunteers, including people with lung cancer, smokers who had not been diagnosed

with lung cancer, and healthy individuals.

Among the 104 people with lung cancer, 103 tested positive for tNOX. In smokers older than 40, 12% were positive, which Moore

says is about the normal rate of lung cancer picked up with high resolution CT scanning.

But, in contrast, none of the 25 healthy people tested positive.

Morre says he envisions using a tNOX test as a screening tool for the early detection of lung cancer in high-risk people. Currently,

there is no test able to reliably diagnose lung cancer early, when it is most treatable.

"All heavy smokers over age 50 should be tested for tNOX," he tells WebMD. Those who test positive would then be followed up

with a medical examination and further tests.

A weak signal would indicate early cancer at a stage where it is potentially curable, he adds.

tNOX May be Useful in Other Cancers, Too

The next step is to look at tNOX levels in people with other types of cancer, the researchers say.

Lorraine O'Driscoll, PhD, a cancer researcher at Dublin City University in Ireland, says that while the test could be extremely useful,

she imagines tNOX will be used as part of a panel of markers to detect cancer and monitor its progression.

"There are so many potential candidates out there that I doubt any one will prove to be the one answer," she tells WebMD. "Rather,

we will probably use a combination of markers and tNOX could certainly prove to be one of them."

Saliva Test Spots Cancer

Test Looks for Genetic Fingerprints That Signal Early Oral Cancer

By Charlene Laino

WebMD Health News

April 19, 2005 (Anaheim, Calif.) -- Don't be shocked if your doctor asks you to spit into a cup during a checkup in the near future. A

new study shows that a simple saliva test can detect cancer of the mouth and throat at its earliest stages, even before symptoms

develop.

The test looks for distinct genetic differences in saliva and is over 90% accurate in detecting oral cancer, says David T. Wong, DMD,

DMSc, associate dean of research at the UCLA School of Dentistry and the Jonsson Comprehensive Cancer Center.

His team has already shown that the approach has similar predictive powers for head and neck cancers. And now they're testing the

saliva screen in breast cancer patients as well.

"In the future, one drop of saliva could be screened for all sorts of diseases, not just cancer," Wong tells WebMD. "Unlike tests that

require drawing blood, a saliva test is totally noninvasive."

The findings were presented at the annual meeting of the American Association for Cancer Research.

Genetic Fingerprint Points to Cancer

Analyzing markers in saliva, blood, or other body fluids that signal early cancer has long been a goal of scientists seeking quick,

easy, and reliable screening tests that can be done in a doctor's office.

Many researchers have focused on detecting the proteins produced by cancers. But Wong's team decided to look at the products of

these genes, called RNA.

It wasn't easy developing the test. The breakthrough came only about three years ago, when engineers developed high-tech, highly

sensitive sensors that can detect molecules at minute levels, he says.

The new study shows that the distinct patterns are not only measurable in saliva but can also indicate a developing tumor, he says.

The test showed that saliva contains 3,000 RNA markers. However, Wong's team shows that four patterns created by products of

these genes are enough to pinpoint oral cancer.

The study included 64 people with oral cancer and 64 people without cancer.

The presence of these four patterns predicted with 91% accuracy whether a saliva sample was from a person with oral cancer or a

person without it, Wong says.

Then, the researchers looked at the genetic profile in the participants' blood.

The researchers found a similar pattern for oral cancer in blood as well. "But the accuracy was only 88%. At least for oral cancer,

saliva has a slight edge over blood testing."

By 2007, the researchers hope to identify genetic signatures for at least 10 common diseases, including other cancers, heart

disease, and diabetes, Wong says.

Experts Welcome Early Detection Saliva Test

John Mendelsohn, MD, president of the University of Texas M.D. Anderson Cancer Center in Houston and moderator of a news

conference to discuss the study, says the findings are encouraging.

Being able to predict who will respond to a particular treatment is becoming more and more important, as many of the new targeted

cancer drugs are very selective -- not to mention expensive, he says. Plus, catching cancer early saves lives.

"A test like this meets both these goals," Mendelsohn tells WebMD. And there's a real edge over other tests in development.

"Spitting is a lot easier than giving blood or dragging a stool sample to the doctor," he says.

A n Accurate Blood Test For Cancer

FYI FROM

THE SAN FRANCISCO MEDICAL RESEARCH FOUNDATION

There is now a blood test that will accurately detect early cancer of all types. It has an accuracy of greater than 95%. If the test is repeated, the

accuracy is greater than 99%. That is to say, that false positive and false negative rates are less than 1%. The test is called AMAS.

Twenty one years ago a neurochemist, Samuel Bogoch, M.D., Ph.D., discovered a test for cancer antigen, similar to today's PSA for prostate

cancer and CEA for colorectal cancer. With hard work and good sound research, he found the first anticancer antibody in the bloodstream of

patients with cancer. He named the new antigen malignin, and called new the new antibody Anti Malignin Antibody. Hew founded a laboratory in

Boston called Oncolab, Inc. the test has been finally patented, and the FDA has granted permission to market this test.

We have been following the development of this test for the past five to eight years, however. It was not quite workable as a test that could be

easily utilized by practicing physicians. At present, the test and the procedures in utilizing it have been refined and it is workable. A recent

newsletter from the Friend Foundation For Medical Research, Volume 6, Number 1, Spring 1995, gives a descriptive summary of the AMAS test

to date.

Doctors will be using the AMAS test around the world. There are three indications and uses for this test.

1. A cancer screening test.

The usual examination in a doctor's office today includes a history, a physical examination and selected laboratory tests aimed at detecting

potential problems including cancer. With the use of the AMAS test, the doctor will be able to defer or eliminate chest x rays, sigmoidoscopy, CT

scans, possibly even mammograms and PAP tests, unless the AMAS is abnormal. All blood donors and transplant donors and recipients will be

screened by AMAS to insure there is no chance of spreading undiagnosed viral induced cancer. Life and disability insurance companies will

surely want to know your AMAS status before underwriting a new policy or renewing an old one.

This is exciting to us because we have been prevention minded for our entire medical career. The problem with cancer is that, like other

diseases, it is not detectable until it's advanced. The other exciting idea here is that many cancers will be able to be prevented because tainted

blood transfusions or transplant organs will be able to be screened, preventing the transplantation of cancer into an already sick patient. We all

realize it is better to find a small cancer early than big cancer later. The cancers that are detected at an earlier stage are ones that have the

highest possibility of a permanent cure.

2. A cancer monitoring test.

After any cancer has been treated the patient, as well as the doctor, wants to know if the cancer has been cured or if some malignancy may

remain in the body. Breast cancer is a good example. Published data show that when surgery has been curative, the AMAS value returns to

normal. If any cancer remains, AMAS will continue to be elevated. Cancer specialists will be able to precisely recommend radiation and

chemotherapy only for those patients who need it.

3. In differential diagnosis.

If there is a shadow on a chest x ray, a spot in the liver CT scan, a suspicious area on a mammogram, or an enlarged lymph node on an MRI,

generally a needle biopsy or an open surgical biopsy is necessary to tell whether or not the tissue is cancerous. If the AMAS is normal, the

lesion in question is not a cancer. In the future, the AMAS test should dramatically reduce the number of invasive biopsies, needless pain and

suffering, and reduce the cost of medicine.

COSTS AND AVAILABILITY

AMAS is a test which measures an antibody. It is a laboratory procedure called an immunoassay. PSA for prostate cancer and CEA for

colorectal cancer are two common immunoassay that measure antigens. At the present time, AMAS is only available through Dr. Bogoch's

Oncolab, Inc. in Boston. The requisition to order AMAS must contain specific medical information and must be sighed by both patient and

physician.

The test is presently done by hand at Oncolab and requires special handling including properly separating the serum from the blood, freezing

and shipping overnight to Boston. Dr. Bogoch is currently attempting to place AMAS with a strong international company that will make the test

affordable and available in an automated form worldwide. He hopes to accomplish this by the end of 1995.

AMAS AND BREAST CANCER

To date, more than 1,000 patients with breast cancer have been studied with AMAS. Most of the clinical research has focused on using AMAS to

tell if the cancer has been cured. Results show that breast cancer can only be presumed cured if the AMAS returns to normal level after

treatment. New data shows convincing evidence that breast cancer cannot be presumed to be in remission unless AMAS returns to normal.

Traditionally, the usual follow up treatment would include CT scans, MRI's, x rays and hormonal blood tests, looking for signs of cancer after

treatment. Used and performed properly, AMAS gives a much more accurate answer at a fraction of the cost and inconvenience. AMAS has

found breast cancer as small as a pencil dot. This is a truly remarkable test.

THE FUTURE FOR CANCER DETECTION AND TREATMENT

Dr. William J. Friend, M.D., the Director of Medical Research for The Friend Foundation, states that Anti Malignant Antibody in Serum (AMAS) is

a naturally occurring antibody present in the serum of all people, even children. AMAS is our natural immune system against cancer. The test

can be used to determine if any type of cancer exists anywhere in the body. It will tell if the new treatment against any cancer has been

successful. The future application of AMAS in vaccines and booster shots is inevitable. Historians will probably view AMAS as the most

important diagnostic test of the twentieth century, as it will forever change the practice of medicine in the civilized world.

MEDICAL PROGRESS AT LAST

As a new cancer screening test, the AMAS will be invaluable. It's probable that all adults will be screened on an annual basis, perhaps

beginning at about age 35. Some might be screened even earlier if there is cancer in the family history.

Studies on more than 6,000 patients have shown a sensitivity and specificity of AMAS greater than 95% (99% if repeated). Physicians,

especially those in Managed Care and HMO's, are not going to order the routine and conventional cancer screening tests, such as PSA, CEA,

CA 125, x rays, mammograms, fecal occult tests, PAP tests, colonoscopies, etc., unless AMAS is positive. IF the AMAS test is normal, there is a

better than 99% chance that the doctor will not find cancer.

VETERINARY MEDICINE

Veterinarians will also be suing AMAS as it has been detected in goats, dogs, rabbits, and rats. As in humans, there appears to be a normal

level of AMAS that is bumped up when cancer starts growing.

HELPING THE PATHOLOGIST

The pathologists batting average in diagnosing cancer can be greatly improved because AMAS is an antibody that can be stained with a variety

of immunofluorescent dyes. The dyed AMAS readily adheres to cancer cells and under the microscope they stand out and are easily diagnosed.

AMAS MONOCLONAL ANTIBODIES

An antibody is a specific molecule that attacks and neutralizes or kills a specific cell that contains an antigen that has invaded or infected the

body. AMAS is a naturally occurring anti cancer antibody in everyone's serum. today it is relatively easy to precisely duplicate (clone) an

antibody. It is also fairly easy to attach a second molecule to the cloned antibody. If that second molecule is a chemotherapeutic agent, which

could destroy a cancer cell, in addition to AMAS itself, the resultant structure is called a therapeutic monoclonal antibody.

This procedure could result in an intravenous injection that would destroy any type of cancer anywhere in the body without affecting normal

tissue or causing side effects.

AMAS BODY SCANNER

AMAS is at its best when cancers are just getting started and are still small in size. In fact, one of the problems with AMAS is going to be that it

detects cancer so early that your doctor may not be able to find it. AMAS can detect cancers up to 19 months before your doctor can find it. A

unique way to solve this dilemma is to let AMAS detect its antigen. First, label AMAS with a medical radioactive isotope. Everyday, in your local

hospital, doctors routinely label molecules in this way to provide scanning for liver, lungs, heart, kidneys, bones, etc. After the labeled AMAS is

injected intravenously, it wanders around the blood stream and selectively adheres to cancer cells anywhere in the body. Then, the patient can

be scanned with a gamma detecting camera and the location of any "hot spots" are relatively easy to see.

AMAS VACCINES AND BOOSTER SHOTS

AMAS is the antibody against malignin. Malignin is the antigen, or the marker, that AMAS recognizes as cancer. Dr. Bogoch was the first person

to identify malignin, and now produces it at his laboratory in Boston. Malignin can be used as a vaccine to stimulate the immune system to make

the protective and cancer antibody. Dr. Bogoch has also purified the AMAS antibody. AMAS could be injected intravenously as a true

immunologic booster shot. In the human body there is a constant war going on between cancer and AMAS. Isolated reports of spontaneous

cancer cures are undoubtedly the result of natural occurring AMAS.

THE CELL AND CANCER

The cells with similar function grow side by side to form a common tissue, such as brain tissue or muscle tissue or bone tissue. As these normal

cells proliferate, they begin to crowd and bump into each other; and a phenomenon that researchers call cell recognition occurs and a message

is sent back to the individual cells in the tissue to stop proliferating. Cancer cells do not recognize this phenomenon, and they continue to grow

and multiply and cause the tissue to expand into a larger mass called a tumor.

The surface of cancer cells contains an outer coating of sugar molecules over an inner layer of protein molecules. Together they are called

glycoproteins. Unlike normal cells, cancer cells keep crowding and bumping into each other and part of the layer of sugar molecules is ground

off, exposing the inner protein layer, which is the antigen Dr. Bogoch has named malignin.

Due to cell recognition, our immune system spots malignin, also. When it sees malignin, it starts turning out anti malignin antibody, which is our

body's natural defense against all cancers. In 1988, Dr. Bogoch purified AMAS and demonstrated that it would kill cancer cells in the test tube.

Can you imagine the day when we might start treating cancer with booster shots of anti malignin antibody? Dr. Bogoch's contribution to science

and medicine will certainly put him in contention for the Nobel Prize.

Most of the material that you have read comes from the newsletter of the Friend Foundation. This is an exciting breakthrough in cancer

detection, and it is important that all of the general public be aware of this. Acres U.S.A. has made it possible for the reader of the column to be

well up on the information in advance of the general public. The test needs to be automated and widely distributed, and that is what is slowing

down the information and dissemination of the AMAS test. It is, however, available and if you would request it from your doctor, it can be done

for you.

You might also request a copy of the newsletter from which this column came. The address is:

The Friend Foundation, 1221 Madison, Suite 1220, Seattle, WA, 98104

Phone: 206-***-****, fax: 206-***-****.

When the test becomes widely available, and this hinges on the general public having the information and knowledge and requesting the test

from their physicians, a great improvement will be accomplished in our medical care. One could imagine a great amount of money saved from

conventional tests no longer needed. It will be possible to reduce or eliminate the follow up chemotherapy, surgery, and radiation treatments so

commonly prescribed today. There would also be a tremendous elimination of cancer phobia, the fear of getting cancer, so common in our

middle aged population. There would be a tremendous amount of money that would be available to ease life's other burdens.

Greater than 99% of patients with cancer have AMAS levels above 135. AMAS levels below 135 are seen in normal individuals who do not have

cancer. If in doubt, a repeat test is indicated.

Normal levels are also seen in successfully treated cancer patients, in which there is no further evidence of disease.

Dr. Bogoch is to be heartily congratulated for his 20 years of research which is about to bear fruit beneficial to all mankind. The Friend

Foundation is a non profit, tax free public charity dedicated to medical research. They are to be congratulated for their support of Dr. Bogoch.

For further information or additional copies of the brochure, please call or write them.

What Is Cancer?

Cancer is the general name for a group ofmore than 100 diseases in which cells in a part of the body

begin to grow out of control. Although there are many kinds of cancer, they all start because abnormal

cells grow out of control. Untreated cancers can cause serious illness and even death.

How a normal cell becomes cancer

Normal body cells grow, divide, and die in an orderly fashion. During the early years of a person's life,

normal cells divide more quickly until the person becomes an adult. After that, cells in most parts of the

body divide only to replace worn-out or dying cells and to repair injuries.

Cancer cells develop because of damage to DNA. This substance is in every cell and directs all of the

cell's activities. Most of the time when DNA becomes damaged, either the cell dies or is able to repair the

DNA. In cancer cells, the damaged DNA is not repaired. People can inherit damaged DNA, which

accounts for inherited cancers. Many times though, a person’s DNA gets damaged by things in the

environment, like,chemicals, viruses, tobacco smoke or too much sunlight.

How cancers differ

Cancers can begin in many different parts of the body. But, different types of cancer can act very

differently. For example, lung cancer and breast cancer are very different diseases. They grow at different

rates and respond to different treatments. That's why people with cancer need treatment that is aimed at

their particular kind of cancer.

How cancer spreads (metastasis)

Because cancer cells keep growing and dividing, they are different from normal cells. Instead of dying,

they outlive normal cells and continue to grow and make new abnormal cells.

Cancer usually forms as a tumor (a lump or mass.) Some cancers, like leukemia, do not form tumors.

Instead, these cancer cells involve the blood and blood-forming organs, and circulate through other

tissues where they grow.

Cancer cells often travel through the bloodstream or through the lymph system to other parts of the body

where they begin to grow and replace normal tissue. This spreading process is called metastasis.

Even when cancer has spread to a different part of the body it is still named for the place in the body

where it started. For example, breast cancer that has spread to the liver is metastatic breast cancer, not

liver cancer. Prostate cancer that has spread to the bone is called metastatic prostate cancer, not bone

cancer.

Remember that not all tumors are cancerous. Benign (non-cancerous) tumors do not spread to other

parts of the body (metastasize) and are very rarely life-threatening.

How common is cancer?

Half of all men and one-third of all women in the US will develop cancer during their lifetimes. Today,

millions of people are living with cancer or have had cancer. The risk of developing most types of cancer

can be reduced by changes in a person's lifestyle, for example, by quitting smoking, limiting time in the

sun, being physically active, and eating a better diet. The sooner a cancer is found and treated, the better

the chances are for living for many years.

No matter who you are, we can help. Contact us anytime, day or night, for cancer-related information and

support. Call us at 1-800-ACS-2345 or visit www.cancer.org.

Contact this candidate